SPIRIVA RESPIMAT: payments to doctors
Payments that named SPIRIVA RESPIMAT as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $3.6M
- Providers
- 42,343
- Transactions
- 208,335
- Average per transaction
- $17
The per-transaction average — $17 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 42,343 providers the average total is $84, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Boehringer Ingelheim | $3,503,911 | 97.9% |
| Boehringer Ingelheim International GmbH | $73,972 | 2.1% |